



Ulipristal acetate for Emergency Contraception to be included on the Essential Medicines List by the World Health Organization

Paris, France, June 12, 2017 – HRA Pharma, the European leader in emergency contraception, is proud to announce that ulipristal acetate 30 mg for emergency contraception (EC), commercialised under the brand name ellaOne, has been included to the WHO Model List of Essential Medicines (EML).

The WHO Model List of Essential Medicines presents a list of minimum medicine needs for a basic health system. The EML is updated and revised every two years by the WHO Expert Committee on Selection and Use of Medicines.

Camille Banh, Medical manager -Women's health of HRA Pharma comments *“Today’s decision by the WHO highlights that ulipristal acetate 30 mg for emergency contraception is an essential medicine all women should have easy and quick access to. The EML serves as guidance for national and institutional essential medicine lists and we hope the inclusion of ulipristal acetate 30 mg for emergency contraception will be reflected in these local lists, further expanding women’s access to this product across the world, preventing more unplanned pregnancies, especially in developing countries.”*

The EML application, submitted last year by HRA Pharma, was supported by the Department of Reproductive Health and Research from WHO, the European Consortium for Emergency Contraception and the International Consortium for Emergency Contraception. After its recent inclusion in the WHO Medical Eligibility Criteria for Contraceptive Use (2015) and in the WHO Emergency Contraception Factsheet (2016), it is another step in WHO’s recognition of ulipristal acetate in emergency contraception.

About HRA Pharma

HRA Pharma is a fast growing, innovative consumer healthcare company, empowering people throughout the world to improve their lives by developing accessible, value added, self-care solutions. Historically centered on women's health, the company has become the European leader in emergency contraception. With ambitious projects in the pipeline, including innovative Rx-to-OTC switches, HRA Pharma is committed to bringing a range of innovative products and services to market, particularly in areas of unmet customer needs. Headquartered in Paris, France with subsidiaries across Western Europe and a global network of local partners covering over 90 countries, the company has a proven structure, the skills and experience to capture new consumer healthcare businesses and deliver high quality brands on a global scale. Visit www.hra-pharma.com for more information.

###

Media contact

Karina Bugnon

Tel - +33 (0) 1 40 33 11 30

Email – k.bugnon@hra-pharma.com